Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 10 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Ionis Pharmaceuticals Inc | IONS | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 41.55 | 04:00:04 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 41.55 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 1 | 10 | - | 34.32 - 54.4446 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 04:00:00 | 10 | $ 41.24 | USD |
Ionis Pharmaceuticals Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 6.06B | 145.75M | - | 787.65M | -366.29M | -2.51 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Ionis Pharmaceuticals News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical IONS Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 42.69 | 43.38 | 41.26 | 42.32 | 832,353 | -1.14 | -2.67% |
| 1 Month | 41.89 | 44.95 | 41.26 | 43.05 | 920,428 | -0.34 | -0.81% |
| 3 Months | 51.31 | 52.49 | 41.26 | 45.55 | 1,095,578 | -9.76 | -19.02% |
| 6 Months | 47.74 | 54.4446 | 41.26 | 47.60 | 1,134,534 | -6.19 | -12.97% |
| 1 Year | 37.30 | 54.4446 | 34.32 | 44.27 | 1,128,384 | 4.25 | 11.39% |
| 3 Years | 41.04 | 54.4446 | 25.04 | 39.61 | 1,119,999 | 0.51 | 1.24% |
| 5 Years | 84.22 | 85.45 | 25.04 | 46.44 | 1,087,869 | -42.67 | -50.66% |
Ionis Pharmaceuticals Description
| Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy. Ionis subsequently brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). |
